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Abstract
Overt autoantibodies to the smaller isoform of glutamate decarboxylase (GAD65Ab) are a characteristic in patients with
Type 1 diabetes (T1D). Anti-idiotypic antibodies (anti-Id) directed to GAD65Ab effectively prevent the binding of GAD65 to
GAD65Ab in healthy individuals. Levels of GAD65Ab-specific anti-Id are significantly lower in patients with T1D, leading to
overt GAD65Ab in these patients. To determine the possible protective role of GAD65Ab-specific anti-Id in T1D
pathogenesis, we developed the monoclonal anti-Id MAb 8E6G4 specifically targeting human monoclonal GAD65Ab b96.11.
MAb 8E6G4 was demonstrated as a specific anti-Id directed to the antigen binding site of b96.11. MAb 8E6G4 recognized
human antibodies in sera from healthy individuals, T2D patients, and T1D patients as established by ELISA. We confirmed
these MAb 8E6G4-bound human antibodies to contain GAD65Ab by testing the eluted antibodies for binding to GAD65 in
radioligand binding assays. These findings confirm that GAD65Ab are present in sera of individuals, who test GAD65Ab-
negative in conventional detection assays. To test our hypothesis that GAD65Ab-specific anti-Id have an immune
modulatory role in T1D, we injected young Non Obese Diabetic (NOD) mice with MAb 8E6G4. The animals were carefully
monitored for development of T1D for 40 weeks. Infiltration of pancreatic islets by mononuclear cells (insulitis) was
determined to establish the extent of an autoimmune attack on the pancreatic islets. Administration of MAb 8E6G4
significantly reduced the cumulative incidence rate of T1D and delayed the time of onset. Insulitis was significantly less
severe in animals that received MAb 8E6G4 as compared to control animals. These results support our hypothesis that anti-
Id specific to GAD65Ab have a protective role in T1D.
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Introduction
Autoantibodies to the 65 kd isoform of glutamate decarboxylase
(GAD65Ab) are well-recognized humoral markers of the autoim-
mune response of type 1 diabetes (T1D) [1]. However, our recent
findings suggest that GAD65Ab exist also in healthy individuals,
where their binding to GAD65 is blocked by specific anti-idiotypic
antibodies (anti-Id) [2]. The serum concentration of GAD65Ab-
specific anti-Id in T1D patients is significantly lower as compared
to that in healthy individuals, resulting in the easy detection of
GAD65Ab using conventional radioligand binding assays [2].
According to the ‘‘network hypothesis’’ [3], anti-Id and
autoantibodies co-exist to maintain the homeostasis of the immune
system. An imbalance of this network may induce autoimmune
diseases and a negative correlation between anti-Id and autoim-
mune disease has been demonstrated in autoimmune diseases,
such as systemic lupus erythematosus (SLE), Hashimoto’s
thyroiditis, Graves’ disease, Myasthenia Gravis, and Sjo ¨gren’s
syndrome [4–10]. Naturally occurring autoantibody-specific anti-
Id can be detected in relatives of SLE patients [11], individuals
who were in contact with SLE patients [12], and even in healthy
controls [7,13,14]. In marked contrast, these anti-Id are not
present in most patients with active SLE [15,16]. However,
patients in remission from SLE show a resurgence of anti-Id [7],
suggesting a protective role of anti-Id.
Similarly, anti-Id specific to autoantibodies characteristic for
Graves’ disease are associated with remission in Graves’ disease
[17], and have been linked to a better response of patients to anti-
thyroid drugs [18]. These findings further support the notion that
autoantibodies are present in healthy individuals but concealed by
the presence of anti-Id.
The role of anti-Id in the development of autoimmune diseases
is unclear. A potential regulatory function of anti-Id is through
neutralization of pathogenic autoantibodies, a mechanism that
may explain the beneficial use of Intravenous Immunoglobulin in
treatment of autoimmune diseases [19].
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associated human monoclonal GAD65Ab b96.11 into young
non-obese diabetic (NOD) mice induced b96.11-specific anti-Id
and significantly reduced the morbidity of T1D in the animals
[20]. To elucidate the role of anti-Id in the regulation of the
autoimmunity response, we developed a monoclonal anti-Id
targeting the antigen binding site of b96.11. This murine anti-
Id (MAb 8E6G4) is b96.11-specific and targets the antigen
binding site of b96.11, preventing binding of GAD65 to b96.11
and not to other GAD65Ab. MAb 8E6G4 was successfully used
to detect GAD65Ab in sera of individuals, who tested
GAD65Ab-negative in conventional detection assays. We found
that the levels of masked GAD65Ab in T1D patients and T2D
patients were significantly higher than those in healthy
individuals. Finally, injection of NOD mice with MAb 8E6G4
significantly reduced severity of insulitis and resulted in reduced
incidence rate of diabetes. These findings suggest an immune
modulatory role of GAD65Ab-specific anti-Id in the develop-
ment of T1D.
Results
Development of monoclonal antibody 8E6G4 specific to
b96.11
Animals responding to b96.11-injections with production of
b96.11-reactive antibodies were identified by ELISA (data not
shown). One animal showed good binding to b96.11 even at
1:256,000 dilution, while no binding to the control antibody hLF
was detected. Hybridoma 8E6G4 was generated from this animal.
MAb 8E6G4 binds to human GAD65Ab b96.11 with high
specificity and affinity
We characterized the binding of MAb 8E6G4 to b96.11 by dot-
blot, ELISA, and immunoprecipitation. The dot blot analysis
demonstrated that b96.11 showed significant binding to MAb
8E6G4 (both purified and supernatant) and did not bind BSA
(Figure 1A). This specificity of MAb 8E6G4 was further
established in immunoprecipitations where MAb 8E6G4 was
incubated with b96.11 or control antibody hLF. The immune
complexes were immunoprecipitated with Protein L-agarose [21],
which binds only to kappa light chains and not lambda light
chains. As b96.11 contains a lambda light chain this allowed the
specific precipitation of MAb 8E6G4. Only b96.11 and not the
control antibody hLF were detected in the subsequent analysis of
the co-immunoprecipitated antibody by Western Blot analysis
(Figure 1B). The dissociation constant (Kds) of MAb 8E6G4 to
b96.11 was determined as 480.4 pM by non-competing ELISA
(Figure 1C).
MAb 8E6G4 binding to GAD65Ab b96.11 is specifically
blocked by GAD65
To establish the binding site of MAb 8E6G4, binding of MAb
8E6G4 to b96.11 was competed with recombinant GAD65 in a
competitive ELISA (Figure 2A). We found that recombinant
GAD65 significantly reduced MAb 8E6G4 binding to b96.11 in a
specific and dose-dependent manner. This result strongly
indicated that MAb 8E6G4 recognizes the antigen binding site
of b96.11.
Binding of MAb 8E6G4 to GAD65Ab b96.11 is antibody-
specific
The epitope specificity of MAb 8E6G4 was further explored by
testing the binding of MAb 8E6G4 to b96.11 and other
monoclonal GAD65Ab. Human GAD65-specific monoclonal
antibodies b96.11 and b78 and mouse GAD65-specific monoclo-
nal antibody N-GAD65mAb were incubated at their respective
half-maximal binding concentrations (150, 800, and 40 ng/ml,
respectively) with different concentrations of MAb 8E6G4 (0–
0.32 mg/ml). Binding of the GAD65-specific monoclonal antibod-
ies to radiolabeled GAD65 in the presence of MAb 8E6G4 was
analyzed by RBA (Figure 2B). We found that only binding of
b96.11 to GAD65 was inhibited by MAb 8E6G4, while binding of
GAD65 by b78 or N-GAD65mAb was not affected. These
findings support that MAb 8E6G4 is a b96.11-specific anti-Id that
binds to the antigen-binding region of b96.11.
Sequence analysis of the heavy and light chain of MAb
8E6G4
The variable region protein sequences deduced from the
nucleotide sequences were aligned for comparison with homolo-
gous sequences from the NCBI data bank. The nucleotide
sequences for both heavy and kappa chain genes were submitted
to GenBank under accession numbers JF345172 and JF345173,
respectively. Sequence analysis of the heavy-chain-specific cDNA
revealed that the heavy chain belonged to the mouse IgG heavy
chain subgroup 1. Sequence analysis of the light-chain cDNA and
database comparison revealed that the light belonged to the mouse
kappa light-chain group 4–59. Comparison of the nucleotide
sequences of the heavy- and light-chains with GenBank databases
revealed no identity to previously reported sequences. The
accuracy of the deduced amino acid sequence was verified by
Mass Spectrometry analysis of purified MAb 8E6G4.
Figure 1. MAb 8E6G4 binds specifically to b96.11. A: Purified
MAb 8E6G4, supernatant of hybridoma 8E6G4, or BSA were analyzed for
binding by b96.11 by Dot blot. From left: supernatant of hybridoma
8E6G4, purified MAb 8E6G4, and BSA. B: Binding of MAb 8E6G4 and
supernatant of hybridoma 8E6G4 to b96.11 was analyzed by
immunoprecipitation followed by Western blot analysis. Binding of
MAb 8E6G4 to control antibody hLF served as negative control. From
left: supernatant of hybridoma 8E6G4 with b96.11, MAb 8E6G4 with
b96.11, and MAb 8E6G4 with hLF. C: MAb 8E6G4 binds to b96.11 with
high affinity. Dissociation constant was calculated by non-competing
ELISA. Different concentrations of b96.11 were tested for binding by
MAb 8E6G4. Kd of each concentration was calculated. The Kd was
calculated as follows: Kd=2(nKd9-Kd)/(n-1), where n=[b96.11]9/
[b96.11]. The average Kd calculated was 480.4 pM.
doi:10.1371/journal.pone.0032515.g001
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Previously we reported that sera that tested GAD65Ab-
negative in conventional RBA, contained GAD65Ab in complex
with anti-Id [2]. Removal of anti-Id allowed the detection of the
GAD65Ab. To confirm these earlier findings we tested whether
MAb 8E6G4 could detect GAD65Ab in sera of individuals,
especially in healthy individuals and T2D patients, whose sera
did not contain overt GAD65Ab. Initially we tested sera
obtained from GAD65Ab-negative T2D patients (n=22),
healthy individuals (n=40), and T1D patients (n=10) by ELISA
(Figure 3A). Of the ten T1D patients six sera tested GAD65Ab-
positive.
We observed that human antibody bound specifically to MAb
8E6G4, while only four of the T2D patients’ sera showed binding
to the control mouse antibodies. Binding levels in T1D patients
and T2D patients significantly exceeded those observed in healthy
individuals (p,0.0001). Binding levels in T1D patients and T2D
patients did not differ significantly. Human antibodies in sera from
GAD65Ab-positive and GAD65Ab-negative T1D patients bound
equally well to MAb 8E6G4.
We established that the MAb 8E6G4-bound human antibody
contained GAD65Ab by testing the eluted antibody for binding to
GAD65 (Figure 3B). Sera of 40 GAD65Ab-negative healthy
individuals were incubated with MAb 8E6G4-PAS and subse-
quently eluted with high pH. Elutions were immediately
neutralized and tested for binding to GAD65 in RBA. Binding
levels significantly increased (from a median GAD65Ab index of
0.02 to a median GAD65Ab index of 0.06) (p,0.0001). No
significant increase in binding to islet cell autoantigen IA-2 was
observed (data not shown). These findings confirm our earlier
observation of GAD65Ab in sera of healthy individuals.
Injections of NOD mice with MAb 8E6G4 significantly
delays the onset and reduces the incidence rate of
diabetes
Animals were injected with MAb 8E6G4, a control mouse
monoclonal antibody, or PBS. The animals were monitored
Figure 2. MAb 8E6G4 competes with b96.11 for binding to
GAD65. A: GAD65 was translated in vitro using rabbit reticulocyte
lysate. Different amounts (0–40 ml, corresponding to 0–160 ng) of
recombinant GAD65 were incubated with 1.4 mg/ml MAb 8E6G4 and
subsequently analyzed for binding to b96.11 by ELISA. Rabbit
reticulocyte lysate alone was used as a negative control (open squares).
Binding in the absence of competitor was set as 100%. B: Binding of
monoclonal GAD65Ab b96.11 (black squares), b78 (open squares), and
N-GAD65mAb (open circles) to radiolabeled GAD65 in the presence of
the indicated concentrations of MAb 8E6G4 was determined. Binding is
reported at percent binding, binding of the respective antibody to
radiolabeled GAD65 in the absence of MAb 8E6G4 is set as 100%.
doi:10.1371/journal.pone.0032515.g002
Figure 3. MAb 8E6G4 binds GAD65Ab present in human sera.
A: Human sera obtained from GAD65Ab-negative healthy individuals
(circles) (n=40), GAD65Ab-negative T2D patients (squares) (n=22), and
T1D patients (diamonds) (n=10), were analyzed for binding to MAb
8E6G4 by ELISA. Binding of human sera to three mouse monoclonal
antibodies specific to human HGF is shown as a negative control (open
symbols). Median binding is indicated. B: Human sera obtained from
healthy individuals (n=40) (GAD65Ab-negative in RBA) were tested for
presence of masked GAD65Ab. Sera were precipitated on immobilized
MAb 8E6G4, and subsequently eluted. Elutions were tested for presence
of GAD65Ab by RBA. GAD65Ab titers of sera prior to precipitation (black
circles) and elutions (open circles) are presented as GAD65Ab index.
Median binding is indicated.
doi:10.1371/journal.pone.0032515.g003
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to develop diabetes at five weeks of age and 10/12 (83%) animals
developed diabetes by week 30, confirming the expected natural
development of diabetes in NOD mice. Injection with control
monoclonal antibody had no significant effect on the development
of T1D. However, injections with 50 and 100 mg MAb 8E6G4
yielded a cumulative incidence rate of 8%, and 17%, respectively.
The animals in the lower dose group developed diabetes at week
25 and 32, the only animal in the 100 mg group developed
diabetes at week 27 (Figure 4). The reductions in incidence rate
and delay in onset observed in animals injected with 50 mgo r
100 mg MAb 8E6G4 was significant compared to control animals
(p=0.0006 and p=0.0002, respectively).
MAb 8E6G4 reduces the severity of insulitis
The above effect was also reflected in the severity of insulitis.
Insulitis was less severe in animals treated with 50 and 100 mg
MAb 8E6G4 IgG as compared to the animals injected with PBS or
control IgG (Table 1, Figure 5).
Discussion
In this study, we tested our hypothesis that anti-Id specific to
GAD65Ab have a protective immune modulatory role in the
development of T1D. We developed and characterized a
monoclonal anti-Id (MAb 8E6G4) targeting the antigen-binding
site of human monoclonal GAD65Ab b96.11. This murine
antibody is specific to b96.11 and blocks binding of GAD65 to
b96.11 meeting the criteria of a b96.11-specific anti-Id. MAb
8E6G4 bound to both overt and masked human antibodies in sera
of T2D patients, T1D patients, and healthy individuals. We
showed that the MAb 8E6G4-bound human antibodies contained
GAD65Ab, confirming our earlier findings of the presence of
GAD65Ab in healthy individuals [2]. The significantly higher
levels of masked GAD65Ab in T2D patients as compared to
healthy individuals may suggest islet autoreactivity in these
patients [22]. Follow-up studies to determine the development of
autoimmune diabetes in these patients are necessary to confirm
this hypothesis.
Administration of MAb 8E6G4 to prediabetic NOD mice
successfully reduced the severity of insulitis in the animals.
Consequently, diabetes incidence was significantly reduced and
age of onset was delayed as compared to control animals. This
effect was antibody-specific, since administration of control mouse
monoclonal antibody had no effect on the development of
diabetes.
Successful prevention of diabetes in NOD mice has been
achieved by a variety of approaches, including vaccination with
autoantigens, manipulation of immune cells, cytokine or vitamin
treatment [23–26]. While the isotype-control in the NOD
injection protocol suggests that the preventative effect of MAb
8E6G4 is antibody specific, more studies are necessary to confirm
this anti-Id as a novel treatment approach in NOD mice. In future
studies we will determine the mechanisms by which MAb 8E6G4
affects the immune response. MAb 8E6G4 may function as an
internal image of the antigen-binding site of b96.11, thereby
mimicking GAD65 vaccination. Alternatively MAb 8E6G4 could
modulate antigen presentation as discussed later.
In the Idiotypic Network Hypothesis, Jerne postulated that
under normal condition antibodies are kept in homeostasis by a
network of idiotypic antibodies (Ab1) and their anti-Id (Ab2) [3]).
When the anti-Id binds to the complementary determine region
(CDR) of Ab1, it can compete the binding of Ab1 to antigen
[27,28]. The invasion of pathogen or the exposure of autoantigen
breaks the balance and leads to the domination of Ab1.
T1D is recognized as a cell-mediated autoimmune disease [29].
However, recent studies indicate a role of the humoral immune
response in the pathogenesis of T1D, mainly through modulation
and/or mediation of antigen presentation. Autoantibodies can
enhance antigen presentation, thus lowering the antigen concen-
tration necessary for T cell stimulation [30]. Depletion of B
lymphocytes by anti-CD20 antibody delays onset of T1D in NOD
Figure 4. Cumulative incidence rate of diabetes development. NOD mice were injected with 50 and 100 mg MAb 8E6G4, presented as black
circles and squares, respectively. Control animals were injected with PBS (white circles) or control mouse monoclonal antibody (white squares).
Animals were weekly monitored for diabetes development. Cumulative incidence rate of diabetes development is presented as percentage.
doi:10.1371/journal.pone.0032515.g004
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improved islet beta-cell function, indicating an important role of B
lymphocytes in T1D pathogenesis [32]. However, anti-CD20
treatment does not discriminate between beneficial and patho-
genic B lymphocytes, leading to a weakened immune system. The
specific removal of pathogenic autoantibodies or the neutralization
of pathogenic B lymphocytes would provide a specific therapeutic
strategy. Anti-Id have been shown to accomplish this specific task
in experimental studies [33]. To date, treatment or prevention of
T1D with GAD65Ab-specific anti-Id has not been reported.
However, our previous study suggested that induction of
GAD65Ab-specific anti-Id prevented onset of diabetes in NOD
mice [20]. Even though GAD65 levels in murine pancreatic beta
cells are very low [34], GAD65 is a major autoantigen in the
pathogenesis of T1D in the NOD mouse. GAD65-reactive T cells
present in the NOD mouse are able to adoptively transfer T1D
[35,36], and the development of these GAD65-reactive T cells
depends on the presence of GAD65-reactive B lymphocytes [37–
39]. These findings support the hypothesis that GAD65-reactive B
lymphocytes are essential in disease development.
Our results of successful prevention of T1D by a b96.11-specific
anti-Id not only support our hypothesis of a protective role of anti-
Id in T1D, but they may also open pathways aimed at the
prevention of T1D in human.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all participants or
their legal guardian. This study was approved by the IRB of the
Affiliated Hospital of Nanjing University of Traditional Chinese
Medicine, China, and the IRB of the University of Washington,
Seattle, USA.
The animal studies were approved by the animal care and use
committee of Nanjing University of Traditional Chinese Medicine.
All procedures involving animals obeyed the animal care and use
regulation of the Jiangsu province.
Patient cohorts
T1D patients. Sera of T1D patients (n=10), (mean age: 21.9
years, age range: 12–29 years) were collected from 2008–2011 in
Jiangsu Province Hospital of TCM, Nanjing, China.
T2D patients. GAD65Ab-negative sera of T2D patients
(n=22), (mean age: 59.1 years, age range: 32–86 years) were
collected in Jiangsu Province Hospital of TCM, Nanjing, China.
The patients were classified with T2D according to the 1997
American Diabetes Association criteria. None of these patients was
diagnosed with autoimmune disease.
Table 1. Degree of insulitis in NOD mice.
S c o r e 12345
MAb 8E6G4 50 mg 5 8 3 7 500
MAb 8E6G4 100 mg 6 0 3 4 020
PBS 0 0 13 17 70
Control IgG 0 0 12 17 71
Islets obtained from animals injected with MAb 8E6G4 IgG (50 and 100 mg),
control IgG, and PBS were scored as normal islets (score 1), perivascular/
periductal infiltration (score 2), peri-insulitis (score 3), mild insulitis (,25% of the
islet infiltrated; score 4), and severe insulitis (more than 25% of the islet
infiltrated, score 5). The mean score for each group was calculated by dividing
the total score by the number of islets scored.
doi:10.1371/journal.pone.0032515.t001
Figure 5. The histopathology of pancreatic islets at onset of diabetes or at 40 weeks of age. Representative images of pancreatic islets
from animals injected with 50 mg (A) and 100 mg (B) MAb 8E6G4 IgG, or control animals (C). Pancreatic tissues were sectioned and stained with
hematoxylin and eosin.
doi:10.1371/journal.pone.0032515.g005
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(n=40) (mean age: 53.3 years, age range: 23–76 years) were
collected in Jiangsu Province Hospital of TCM, Nanjing, China
from volunteers who received annual physical examination in the
hospital agreeing to donate blood samples.
Sera from additional healthy individuals (n=40) (age at
sampling .18 years) were selected based on GAD65Ab-titer and
serum volume from a cohort of healthy individuals (n=50). The
samples were collected in 2002 in Seattle, USA. This cohort
consisted of non-diabetic individuals without known autoimmune
disease and no family history of diabetes.
Animals
Balb/c mice were purchased from Shanghai Slack Experimen-
tal Animal Center, Ltd (Shanghai, China) and maintained in the
Experimental Animal Center of Nanjing Medical University of
TCM.
Female NOD mice were purchased at 3 weeks of age (Beijing
China Fukang Biological Technology Co. Ltd, Beijing, China).
The mice were maintained in specific pathogen-free conditions in
the animal facility under the regulation of local government.
Antibodies used in this study
Human monoclonal antibodies b96.11 and b78 specific to
GAD65 were derived from a patient with autoimmune polyendo-
crine syndrome type 2 [40]. B96.11 recognizes an epitope that is
specifically bound by patients with T1D [41]. B78 recognizes an
epitope that is specifically bound by patients with SPS [42]. N-
GAD65mAb is a mouse GAD65-specific monoclonal antibody
that recognizes a linear epitope located at amino acid residues 4–
22 of human GAD65 [43]. The chimeric antibody hLF is specific
to anthrax lethal factor and served as a control antibody. It consists
of the constant region of human immunoglobulin G and the
murine variable region. The mouse monoclonal antibody used as a
control antibody in the NOD injection protocol was a product of
one of the hybridoma generated from Balb/c mice injected with
b96.11 monoclonal antibody (see below). It showed no binding to
b96.11 and its specificity has not been further evaluated. Its isotype
was determined as IgG1 by ELISA (Thermo Fisher Scientific
China, Beijing, China).
Generation of hybridoma cell line MAb 8E6G4
Balb/c mice (4 weeks of age) were immunized with four
intraperitoneal injections, each containing 10 mg b96.11 in
complete (primary injection) or incomplete (booster injections)
Freund’s adjuvant. Sera from immunized animals were tested for
their binding to b96.11. The mouse with the highest titer was
boosted with intravenous injections (both intraperitoneal and
intravenously) of 10 mg of b96.11. Splenocytes were fused with
SP2/0 cells by polyethylene glycol and the hybridoma cells were
selected as previously described (26). Culture supernatants of
confluent cells were screened at different dilutions for antibodies to
b96.11 by ELISA. Cells exhibiting the highest Ab titers were
cloned by limiting dilutions in 96-well microculture plates and
tested for reactivity with b96.11.
Injection of NOD mice with MAb 8E6G4
Young female NOD mice (4 weeks of age) (groups of 12) were
injected intraperitoneal weekly with 50, or 100 mg antibody, or
PBS. The injections continued until the animals reached 40 weeks
of age or developed diabetes. All animals were monitored for the
development of diabetes. Hyperglycemia was determined by
weekly weighing and blood glucose level tests. Blood glucose
levels were measured weekly by Abbott Medisense Optium Xceed
(Abbott Laboratories S.A. Shanghai, China). Diabetes was defined
by blood glucose levels of .13.9 mM for two consecutive weeks.
Upon confirmation of diabetes, the animal was killed. Degree of
insulitis was established for at least 40 islets in each treatment
group.
Insulitis scoring
A minimum of 40 islets/group were scored for insulitis. Scoring
was performed under double-blinded conditions. The degree of
insulitis was graded according to the following: normal islet, score
1; perivascular/periductal infiltration, score 2; peri-insulitis, score
3; mild insulitis (,25% of the islet infiltrated), score 4; and severe
insulitis (more than 25% of the islet infiltrated), score 5.
Cloning of the heavy and light chain sequences
Gene fragments encoding the heavy and light chain of the
antibody were amplified from 8E6G4 hybridoma by RT-PCR as
described previously [13]. PCR was performed using standard
procedures with Taq DNA Polymerase (Qiagen, Valencia, CA) at
an annealing temperature of 60uC. The nucleotide and deduced
amino acid sequence were compared against known sequences in
the NCBI database.
ELISA and competing ELISA
a) Detection of anti-Id specific to b96.11 by
ELISA. Binding of mice serum, supernatant of hybridoma, and
purified MAb8E6G4tob96.11wastested byELISAusingstandard
procedures. Briefly, 96-well plates were coated with human
monoclonal antibody b96.11 or control antibody (1 ng/ml) at 4uC
overnight. Samples were added and incubated for 45 minutes at
37uC. Bound mouse IgG was detected by addition of alkaline
phosphatase-conjugated anti-mouse IgG (1:3,000) (Sigma-Aldrich
China, Inc., Shanghai, China). Optical density (OD) at 405 nm was
measured on Quant Microplane Spectrophotometer (Bio-Tek
China, Beijing, China). For competing ELISA, 1.4 mg/ml MAb
8E6G4 was preincubated with different amounts of in vitro
synthesized GAD65, prior to addition to the coated plates.
b) Detection of GAD65Ab in human sera by ELISA on
immobilized MAb 8E6G4. Human sera of healthy individuals
(n=40), T1D patients (n=10), and T2D patients (n=22) were
tested for the presence of IgG binding to MAb 8E6G4 by ELISA.
96-well plates were coated with MAb 8E6G4 (1 ng/ml) as above.
After blocking with 5% non-fat milk, human sera (50 ml) was
added and incubated at 37u for 30 minutes. The captured human
antibody was detected by horseradish peroxidase (HRP)-
conjugated goat anti-human IgG secondary antibody (1:5,000)
(Beyotime Biotechnology Ltd, Haimen, China). Optical density
(OD) at 450 nm was measured on a Quant Microplane
Spectrophotometer (Bio-Tek China).
Calculation of dissociation constant
The dissociation constant of MAb 8E6G4 was calculated by
non-competing ELISA. Briefly, 96-well plates were coated with
different concentrations of b96.11 (1, 2, and 4 ng/ml) and
incubated with serial dilutions of MAb 8E6G4 (0–16.4 nM).
Bound mouse antibody was detected as described above. The Kd
was calculated as the following formula: Kd=2(nKd9-Kd)/(n-1),
where n=[b96.11]9/[b96.11].
Dot-blot
The supernatant of hybridoma 8E6G4, 50 ng of purified MAb
8E6G4, or 50 ng of bovine serum albumin were spotted onto
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with 10 mg/ml b96.11 at room temperature for 90 minutes.
Bound b96.11 was detected by HRP-conjugated goat anti-human
IgG secondary antibody (1:5,000) (Beyotime Biotechnology Ltd).
Immunoprecipitation (IP) and immunoblotting
a) GAD65Ab b96.11 (10 mg) was incubated with MAb 8E6G4
(10 mg) or 1 ml of supernatant of hybridoma 8E6G4 at room
temperature for 4 hours. MAb 8E6G4 was captured by protein-L
coupled sepharose (80 ml) (Genscript, Hong Kong, China) at 4uC
overnight with continuous rotation. The captured protein
complexes were resolved by SDS-PAGE and transferred to
PVD-membranes. b96.11 was detected as described under Dot
blot.
b) Sera obtained from healthy individuals (1 ml) were incubated
with 100 ml of MAb 8E6G4 immobilized to Sepharose beads for
10 min at 50uC followed by 30 min at 37uC and finally 10 min at
room temperature. After the removal of the supernatant, the beads
were washed extensively with PBS. The bound anti-Id were eluted
by incubation with 0.2 M glycine, pH 10.0 and neutralized. The
eluted fractions were analyzed for GAD65Ab in a RBA.
Radioligand binding assay (RBA)
GAD65Ab were measured as described previously in a RBA
[44]. Briefly, recombinant
35S-GAD65 was produced in an in vitro
coupled transcription and translation system with SP6 RNA
polymerase and nuclease treated rabbit reticulocyte lysate
(Promega, Madison, WI, USA). The in vitro translated 35S-
GAD65 was kept at 270uC and used within 2 weeks of
preparation. Monoclonal antibodies were incubated at the
indicated concentrations with
35S-GAD65 (25,000 of TCA
precipitable radioactivity). After overnight incubation, free
35S-
GAD65 was separated from the antibody-bound tracer by
precipitation with Protein A Sepharose (Invitrogen). The immu-
noprecipitated radioactivity was counted on a Wallac Microbeta
Liquid Scintillation Counter (Perkin Elmer Life and Analytical
Sciences, Inc, Boston, MA, USA). All samples were analyzed in
triplicate determinations. In the Diabetes Antibody Standardiza-
tion Program (DASP) workshop 2005 the GAD65Ab analysis
ranked at 80% sensitivity and 91% specificity.
Statistical analysis
Incidence of diabetes was compared between the different NOD
groups using the nonparametric log rank test. Median GAD65Ab
levels were compared using the non-parametric Wilcoxon signed
rank test. Significance was defined by P,0.05.
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